Platforms
Our ADC technology platforms are generating potential first/best in class assets, combining our novel proprietary payloads with state-of-the-art linker- and conjugation technologies and improved targeting. This includes clinically validated MOAs, dual payloads and tumor specific release.
ADC Technology Powerhouse Generating First/Best-in-Class Assets
Antifolate ADCs
Working to overcome antibody drug conjugate (ADC) resistance as therapies move into earlier treatment lines and in combination, our antifolate platform provides a differentiated and validated MOA with a payload designed to overcome systemic side effects.
Masked Therapeutics (ByonGuard™)
Our innovative universal masking platform, ByonGuard™, is designed to improve the therapeutic index of antibody-based therapies with no bespoke peptides needed.
Phosphonate ADCs (ByonBoost™)
Our ByonBoost™ phosphonate linker-drug platform is aiming to deliver a range of antibody drug conjugates (ADCs) with high compabilitlity for solid oncology and hematological malignancies.
Pipeline
Our diverse pipeline of proprietary next-generation ADCs reflects our expertise in research, lead identification, preclinical/clinical development, process development and manufacturing.
Key Technologies
Byondis has a suite of proprietary technologies available to generate promising clinical candidates. This includes next generation ADCs containing our proprietary duocarmazine linker-drug (LD) technology ByonZine®.
